124 related articles for article (PubMed ID: 35797004)
1. Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.
Shubrook JH; Radin M; Ali SN; Chubb B; DiPietrantonio K; Collings H; Wyn R; Smith M
Adv Ther; 2022 Sep; 39(9):4114-4130. PubMed ID: 35797004
[TBL] [Abstract][Full Text] [Related]
2. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
[TBL] [Abstract][Full Text] [Related]
3. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A
Pharmacoeconomics; 2021 Mar; 39(3):317-330. PubMed ID: 33150566
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
5. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Li J; He K; Ge J; Li C; Jing Z
Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
[TBL] [Abstract][Full Text] [Related]
10. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
[TBL] [Abstract][Full Text] [Related]
11. Patient preferences for newer oral therapies in type 2 diabetes.
Savarese G; Sharma A; Pang C; Wood R; Soleymanlou N
Int J Cardiol; 2023 Jan; 371():526-532. PubMed ID: 36096275
[TBL] [Abstract][Full Text] [Related]
12. Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.
Evans M; Husain M; Srivastava A; Mangla KK; Kuhlman AB; Lingvay I
Adv Ther; 2024 May; 41(5):1843-1859. PubMed ID: 38340253
[TBL] [Abstract][Full Text] [Related]
13. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
14. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
15. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
16. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.
Boye K; Ross M; Mody R; Konig M; Gelhorn H
Diabetes Obes Metab; 2021 Feb; 23(2):508-519. PubMed ID: 33140575
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
18. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis.
Marchesini G; Pasqualetti P; Anichini R; Caputo S; Memoli G; Ponzani P; Resi V; Rizzo M; Serviddio G; Zanette G
Acta Diabetol; 2019 Mar; 56(3):289-299. PubMed ID: 30306406
[TBL] [Abstract][Full Text] [Related]
19. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
